PARP1 and cancer: PARP1 expression levels are correlated with prognosis in patients with cancer, and high PARP1 expression predicts poor survival of patients with AML, while combined treatment using talazoparib and NL101 resulted in strong synergistic effects against AML (Li et al., 2018).